# US 2022/0195461 A1 · Methods and compositions for transgene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0195461 A1
- Document ID: US20220195461A1
- Status: Published application
- Kind: A1
- Application number: 17/603,840
- Filed: 2020-04-15
- Published: 2022-06-23
- Earliest claimed: 2019-04-15
- Assignees: University of Iowa Research Foundation; Spirovant Sciences, Inc.
- Applicants: University of Iowa Research Foundation; Spirovant Sciences, Inc.
- Inventors: John F. Engelhardt; Ziying Yan; Yinghua Tang; Eric Yuen; Shen Lin
- Web page: https://patentgrep.com/patent/US20220195461A1

## CPC

- C12N 15/86: Viral vectors
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 35/761: Adenovirus
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides methods of expressing a transgene in a cell, methods of treating disorders in a subject in need thereof, and pharmaceutical compositions. In particular, the methods involve contacting a cell (e.g., a cell of a subject suffering from a disorder such as cystic fibrosis) with a recombinant adeno-associated virus (rAAV) that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide that includes a transgene in combination with an augmenter of AAV transduction, thereby expressing the transgene in the cell. The disclosure also provides pharmaceutical compositions that include an rAAV that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide including a transgene in combination with one or more augmenters.

## Claims

### Claim 1

A method of expressing a transgene in a cell, the method comprising contacting the cell with (i) a recombinant adeno-associated virus (rAAV) comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a transgene; and (ii) an augmenter of AAV transduction, thereby expressing the transgene in the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the augmenter is a proteasome modulating agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the proteasome modulating agent is an anthracycline, a proteasome inhibitor, a tripeptidyl aldehyde, or a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anthracycline comprises doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, mitoxantrone, or a combination thereof.

### Claim 5

(canceled)

### Claim 6 (depends on 3)

The method of claim 3, wherein the proteasome inhibitor comprises bortezomib, carfilzomib, or ixazomib.

### Claim 7 (depends on 3)

The method of claim 3, wherein the tripeptidyl aldehyde is N-acetyl-l-leucyl-l-leucyl-l-norleucine (LLnL).

### Claim 8 (depends on 1)

The method of claim 1, wherein the cell is contacted sequentially with the rAAV and the augmenter.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cell is contacted simultaneously with the rAAV and the augmenter.

### Claim 10 (depends on 1)

The method of claim 1, wherein contacting the cell with the rAAV and the augmenter results in an increase in expression of the transgene as compared to contacting the cell with the rAAV alone.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the contacting comprises administering the rAAV and the augmenter to a subject.

### Claim 13

A method of treating a disorder in a subject in need thereof, the method comprising administering to the subject (i) a recombinant adeno-associated virus (rAAV) comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a therapeutic transgene; and (ii) an augmenter of AAV transduction, wherein the administering results in expression of the transgene in cells of the subject.

### Claim 14 (depends on 12)

The method of claim 12, wherein the administering is by inhalation, by nebulization, or by aerosolization, or is intranasal, intratracheal, intrabronchial, oral, intravenous, subcutaneous, and/or intramuscular administration.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the cell is an airway epithelial cell.

### Claim 17

(canceled)

### Claim 18 (depends on 13)

The method of claim 13, wherein the disorder is cystic fibrosis.

### Claim 19 (depends on 1)

The method of claim 1, wherein the transgene is CFTR or a CFTRΔR derivative thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 13)

The method of claim 13, wherein the AV.TL65 capsid protein comprises the amino acid sequence of
(SEQ ID NO: 13)
MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYK
YLGPFNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADAEFQE
RLKEDTSFGGNLGRAVFQAKKRVLEPFGLVEEGAKTAPTGKRIDDHFPKRK
KARTEEDSKPSTSSDAEAGPSGSQQLQIPAQPASSLGADTMSAGGGGPLGD
NNQGADGVGNASGDWHCDSTWMGDRVVTKSTRTWVLPSYNNHQYREIKSGS
VDGSNANAYFGYSTPWGYFDFNRFHSHWSPRDWQRLINNYWGFRPRSLRVK
IFNIQVKEVTVQDSTTTIANNLTSTVQVFTDDDYQLPYVVGNGTEGCLPAF
PPQVFTLPQYGYATLNRDNTENPTERSSFFCLEYFPSKMLRTGNNFEFTYN
FEEVPFHSSFAPSQNLFKLANPLVDQYLYRFVSTNNTGGVQFNKNLAGRYA
NTYKNWFPGPMGRTQGWNLGSGVNRASVSAFATTNRMELEGASYQVPPQPN
GMTNNLQGSNTYALENTMIFNSQPANPGTTATYLEGNMLITSESETQPVNR
VAYNVGGQMATNNQSSTTAPTTGTYNLQEIVPGSVWMERDVYLQGPIWAKI
PETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVPGNITSFSDVPVSSFITQY
STGQVTVEMEWELKKENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTR
PIGTRYLTRPL.

### Claim 22

A pharmaceutical composition comprising (i) an rAAV comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a transgene; and (ii) an augmenter of AAV transduction.

### Claim 23 (depends on 22)

The pharmaceutical composition of claim 22, wherein the augmenter is a proteasome modulating agent.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the proteasome modulating agent is an anthracycline, a proteasome inhibitor, a tripeptidyl aldehyde, or a combination thereof.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the anthracycline comprises doxorubicin, idarubicin, aclarubicin, daunorubicin, epirubicin, valrubicin, mitoxantrone, or a combination thereof.

### Claim at position 26

26-28. (canceled)
